Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints leading oncologist to board

Thomas Lynch is director of Yale Cancer Center

BMS Thomas LynchBristol-Myers Squibb (BMS) has appointed one of the world's leading oncologists to its board of directors.

Dr Thomas Lynch, who is currently director of the Yale Cancer Center, will join the pharma company's science and technology committee.

In addition to his role at Yale, Dr Lynch is also physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven in the US, as well as professor of medical oncology at the same hospital.

Lamberto Andreotti, CEO of BMS, praised both Dr Lynch's work in cancer as well as his business leadership.

“As we advance our work in immuno-oncology and build our leadership position in oncology, his guidance and scientific and business perspectives will be invaluable,” said Andreotti.

Prior to his current roles at Yale, Dr Lynch was a professor of medicine at Harvard Medical School and chief of haematology and oncology at Massachusetts General Hospital (MGH) Cancer Center.

He also served as director of the Center for Thoracic Cancers at MGH and director of medical oncology at MGH Thoracic Oncology Center.

13th December 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics